Presentation

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

Presenter: Michelle L. O’Donoghue

May 07, 2018

REGISTER for free or LOG IN to view this content

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

Clinical Cardiology

Clinical Pharma

Lipids

Presentation

EAS 2018

Up Next

Presentation

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Presenter: Brian A. Ference

May 07, 2018

More slides +

Presentation

12-Month Results From First-in-Human Randomized Study of Ranger DCB for Femoropopliteal Treatment

May 08, 2018

Presentation

Causes and Associated Costs of 30-Day Readmission of TAVR vs SAVR in the US

May 11, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.